Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Akorn, Sofgen Pharma Sign Development/Supply Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Akorn, Sofgen Pharma Sign Development/Supply Pact

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Akorn, Inc. has signed an exclusive licensing, development and supply agreement with Sofgen Pharmaceuticals for the development of an ANDA oral drug product for women’s healthcare. Financial terms of the agreement were not disclosed.

Sofgen will be responsible for development and manufacturing of the drug and Akorn will be responsible for the regulatory submission, marketing and distribution in the U.S. and PR. The two companies are expected to begin a Bioequivalence study this October with a projected launch date in late 2009.

Arthur S. Przybyl, Akorn’s president and chief executive officer stated, “On September 7, 2007 we previously announced an ANDA filing in collaboration with Sofgen. Building upon that success, we look forward to working together again. This soft gel oral drug product will be the second addition to our pipeline in women’s healthcare and potentially a significant revenue contributor for both companies.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters